Market Overview:
The global LAMEA oncology/anti-cancer drugs market is expected to register a CAGR of 7.8% during the forecast period 2018-2030. The growth in this market can be attributed to factors such as increasing incidence of cancer, rising demand for novel therapies, and growing awareness about cancer treatments. Based on type, the blood cancer segment is expected to account for the largest share of the global LAMEA oncology/anti-cancer drugs market in 2018. This segment is also projected to grow at the highest CAGR during the forecast period. Oncology/anti-cancer drugs are used for various types of cancers such as blood cancer (leukemia and lymphoma), breast cancer, gastrointestinal cancer (colon and rectal cancers), prostate cancer, and others (head & neck cancers). Among these types, blood cancers are more common than other types of cancers. Increasing incidence rates of leukemia and lymphoma across different geographies are contributing significantly to growth in this segment. Based on application, chemotherapy is estimated to account for the largest share of the global LAMEA oncology/anti-cancer drugs market in 2018 followed by targeted therapy. However; immunotherapy (biologic therapy) is projected grow at a higher CAGR overthe forecast period owingto its high potential benefits over traditional chemotherapy regimens .
Product Definition:
LAMEA Oncology/Anti-cancer drugs are used to treat cancer. They may be used to prevent cancer, slow its growth, or kill cancer cells.
Blood Cancer:
Blood cancer, also known as haemato-oncology is a disease in which the abnormal growth of blood cells causes damage to the blood vessels and other body parts. Haemato-oncology includes four major types: lymphoma, myeloma, multiple myeloma and leukemia. The most common type of blood cancer is lymphoma which accounts for around 80% cases globally followed by Myeloma (mystery meat disease).
Breast Cancer:
Breast cancer is a malignant tumor that develops in the milk ducts of the breast. It is one of the most common types of cancer diagnosed among women, especially after menopause. According to WHO, it accounted for 627,000 new cases and 474 deaths in 2012 (the latest year for which data are available).
Application Insights:
The chemotherapy segment dominated the global market in 2017. This is attributed to the increasing use of this method for treating various types of cancer, such as breast cancer and gastrointestinal cancers. In addition, targeted therapy is gaining popularity due to its ability to deliver high doses of drugs at specific sites in the body. For instance, Velcade is an immunotherapy drug used for the treatment of hormone-sensitive prostate cancer. It works by stimulating a patient¢â‚¬â„¢s immune system against prostate tumor cells.
However, hormonal therapy and targeted/immunotherapy therapies are anticipated to witness lucrative growth during the forecast period owing to their non-invasive nature and fewer side effects associated with them over chemotherapy drugs.
Regional Analysis:
North America dominated the global market in 2017. Key factors contributing to its growth include favorable government initiatives, increasing R&D investments by companies, and high prevalence of cancer in this region. For instance, every year U.S.-based organizations like American Cancer Society (ACS) conduct different campaigns to create awareness about oncology drugs and encourage people with cancer to take part in clinical trials for new treatment options as an alternative to conventional therapies that are not effective or have harmful effects on patients' health.
Asia Pacific is expected to be the fastest-growing regional market during the forecast period owing to rising healthcare expenditure by governments and private sectors along with increasing patient pool seeking treatment for various cancers at hospitals & clinics across this region due mainly expansion of insurance coverage over a large population base which makes it lucrative for players operating in this space as well as potential investors looking forward investing opportunities offered by such companies operating within Asia Pacific LAMEA Oncology/Anti-cancer Drugs Market space.
Growth Factors:
- Increasing incidence of cancer: The incidence of cancer is increasing at an alarming rate in the LAMEA region. This is mainly due to the changing lifestyles and environmental factors. This, in turn, is driving the demand for oncology drugs in the region.
- Rising awareness about cancer: There is a growing awareness about different types of cancers among people in LAMEA countries. This has led to an increase in the number of people seeking treatment for various types of cancers. This, in turn, is boosting demand for oncology drugs in the region.
- Availability of government funding for cancer research: A number of governments across LAMEA are investing heavily in cancer research and this is aiding development of new oncology drugs products In addition, many governments are providing subsidies and other financial assistance to patients suffering from cancer, which is also propelling growth prospects for this market segment over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
LAMEA Oncology/Anti-cancer drugs Market Research Report
By Type
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Others
By Application
Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others
By Companies
Roche, Novartis, Celgene, Amgen, Johnson & Johnson, GlaxoSmithKline, Eli lilly & Co, Pfizer, Merck & Co., Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global LAMEA Oncology/Anti-cancer drugs Market Report Segments:
The global LAMEA Oncology/Anti-cancer drugs market is segmented on the basis of:
Types
Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- Celgene
- Amgen
- Johnson & Johnson
- GlaxoSmithKline
- Eli lilly & Co
- Pfizer
- Merck & Co.
- Sanofi
Highlights of The LAMEA Oncology/Anti-cancer drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Blood Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Others
- By Application:
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the LAMEA Oncology/Anti-cancer drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
LAMEA Oncology/Anti-cancer drugs are medications used to treat cancer. They can be classified by their mechanism of action, which is how they stop or slow the growth of cancer cells. Some common types of LAMEA Oncology/Anti-cancer drugs include chemotherapy, targeted therapy, and immunotherapy.
Some of the key players operating in the lamea oncology/anti-cancer drugs market are Roche, Novartis, Celgene, Amgen, Johnson & Johnson, GlaxoSmithKline, Eli lilly & Co, Pfizer, Merck & Co., Sanofi.
The lamea oncology/anti-cancer drugs market is expected to grow at a compound annual growth rate of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. LAMEA Oncology/Anti-cancer drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. LAMEA Oncology/Anti-cancer drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. LAMEA Oncology/Anti-cancer drugs Market - Supply Chain
4.5. Global LAMEA Oncology/Anti-cancer drugs Market Forecast
4.5.1. LAMEA Oncology/Anti-cancer drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. LAMEA Oncology/Anti-cancer drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. LAMEA Oncology/Anti-cancer drugs Market Absolute $ Opportunity
5. Global LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Type
5.3.1. Blood Cancer
5.3.2. Breast Cancer
5.3.3. Gastrointestinal Cancer
5.3.4. Prostate Cancer
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Application
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.3. Immunotherapy (Biologic Therapy)
6.3.4. Hormonal Therapy
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global LAMEA Oncology/Anti-cancer drugs Demand Share Forecast, 2019-2029
9. North America LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Application
9.4.1. Chemotherapy
9.4.2. Targeted Therapy
9.4.3. Immunotherapy (Biologic Therapy)
9.4.4. Hormonal Therapy
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Type
9.7.1. Blood Cancer
9.7.2. Breast Cancer
9.7.3. Gastrointestinal Cancer
9.7.4. Prostate Cancer
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America LAMEA Oncology/Anti-cancer drugs Demand Share Forecast, 2019-2029
10. Latin America LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Application
10.4.1. Chemotherapy
10.4.2. Targeted Therapy
10.4.3. Immunotherapy (Biologic Therapy)
10.4.4. Hormonal Therapy
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Type
10.7.1. Blood Cancer
10.7.2. Breast Cancer
10.7.3. Gastrointestinal Cancer
10.7.4. Prostate Cancer
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America LAMEA Oncology/Anti-cancer drugs Demand Share Forecast, 2019-2029
11. Europe LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Application
11.4.1. Chemotherapy
11.4.2. Targeted Therapy
11.4.3. Immunotherapy (Biologic Therapy)
11.4.4. Hormonal Therapy
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Type
11.7.1. Blood Cancer
11.7.2. Breast Cancer
11.7.3. Gastrointestinal Cancer
11.7.4. Prostate Cancer
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe LAMEA Oncology/Anti-cancer drugs Demand Share, 2019-2029
12. Asia Pacific LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Application
12.4.1. Chemotherapy
12.4.2. Targeted Therapy
12.4.3. Immunotherapy (Biologic Therapy)
12.4.4. Hormonal Therapy
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Type
12.7.1. Blood Cancer
12.7.2. Breast Cancer
12.7.3. Gastrointestinal Cancer
12.7.4. Prostate Cancer
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific LAMEA Oncology/Anti-cancer drugs Demand Share, 2019-2029
13. Middle East & Africa LAMEA Oncology/Anti-cancer drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Application
13.4.1. Chemotherapy
13.4.2. Targeted Therapy
13.4.3. Immunotherapy (Biologic Therapy)
13.4.4. Hormonal Therapy
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa LAMEA Oncology/Anti-cancer drugs Market Size and Volume Forecast by Type
13.7.1. Blood Cancer
13.7.2. Breast Cancer
13.7.3. Gastrointestinal Cancer
13.7.4. Prostate Cancer
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa LAMEA Oncology/Anti-cancer drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global LAMEA Oncology/Anti-cancer drugs Market: Market Share Analysis
14.2. LAMEA Oncology/Anti-cancer drugs Distributors and Customers
14.3. LAMEA Oncology/Anti-cancer drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celgene
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Amgen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Johnson & Johnson
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. GlaxoSmithKline
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Eli lilly & Co
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Pfizer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Merck & Co.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Sanofi
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
